Skip to main content
2024 Guide to Patient Support Services

Kite Pharma

2024 PSS Guide

Kite Pharma/Kite Konnect

Kite Pharma offers Kite Konnect, a program committed to helping patients and healthcare teams throughout treatment with Tecartus or Yescarta (Table).

Kite Konnect

This program supports healthcare providers and patients throughout each step of treatment with a Kite therapy to include finding CAR T Authorized Treatment Centers, logistics support, reimbursement support, patient therapy enrollment, as well as access to Kite Konnect Case Managers.

Finding a Treatment Center/Patient Enrollment

If you practice at an Authorized Treatment Center, you can enroll your patient for therapy using the Kite Konnect Hospital Portal found at KiteKonnect.com.

For community physicians, you can help your patient take their first step toward treatment by locating an Authorized Treatment Center. To learn more about patient eligibility and to make a referral, please visit the HCP Community Portal found at Kite Konnect Enroll.

Logistics Support

Patients can learn about potential resources for transportation and housing assistance while on a Kite Pharma therapy. To learn more, visit Kite Konnect Support.

Reimbursement Support

Kite Konnect can help with benefits investigations, claims appeals information, and potential sources of support for eligible uninsured and underinsured patients.

TABLE Kite Pharma Oncology Drugs

Drugs
Indications
Patient support programs

Drug
Tecartus (brexucabtagene autoleucel)
Indications
Treatment of adult patients with relapsed or refractory mantle-cell lymphoma; treatment of adult patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia
Patient support program

Drug
Yescarta (axicabtagene ciloleucel)
Indications
Patient support program

Yescarta (axicabtagene ciloleucel) Indications

Treatment of adult patients with B-cell lymphoma that is refractory to first-line chemoimmunotherapy or that relapses within 12 months of first-line chemoimmunotherapy; treatment of adult patients with relapsed or refractory large B-cell lymphoma after 2 or more lines of systemic therapy, including diffuse large B-cell lymphoma (DLBCL) not otherwise specified, primary mediastinal large B-cell lymphoma, high-grade B-cell lymphoma, and DLBCL arising from follicular lymphoma; treatment of adult patients with relapsed or refractory follicular lymphoma after 2 or more lines of systemic therapy